Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Related GSK
Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines
#PreMarket Primer: Thursday, December 4: Beige Book Paints Positive Picture Of U.S. Economy
Action in Ebola-Related Stocks (Fox Business)
Related THRX
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Barron's Recap: Ready To Wear?

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...

Get Benzinga's Newsletters